Showing results (1-10 of 190) with videos related to
Sort By:
Pageof 19
Drugs|January 11, 2017
Treating HIV Infection in the Central Nervous SystemA Calcagno, G Di Perri, S BonoraThe Journal of Infection|June 14, 2008
Moxifloxacin for the treatment of HIV-associated tuberculosis in patients with contraindications or intolerance to rifamycinsS Bonora, A Mondo, L Trentini, et al.Le Infezioni in Medicina|August 8, 2006
[Clinical pharmacology of nucleoside and nucleotide reverse transcriptase inhibitors]S Bonora, A Calcagno, D Gonzalez de Requena, et al.Infection|August 15, 2016
HCV NS3 naturally occurring variants in HIV/HCV coinfected DAA-naïve patients: consideration for HCV genotyping resistance testingT Ruggiero, E Burdino, A Calcagno, et al.The Journal of Antimicrobial Chemotherapy|March 27, 2020
Antiretroviral concentrations in the presence and absence of valproic acidA Calcagno, J Cusato, M Ferrara, et al.The Pharmacogenomics Journal|October 7, 2015
Clinical pharmacology of tenofovir clearance: a pharmacokinetic/pharmacogenetic study on plasma and urinesA Calcagno, J Cusato, L Marinaro, et al.Journal of Neurochemistry|January 9, 2026
The Influence of Blood Brain Barrier Permeability on CSF-To-Serum Ratios of Neurobiomarkers in People With HIVJ Cusato, M Antonucci, M Trunfio, et al.Journal of Medical Virology|October 21, 2025
The Clinical Presentations of Patients With COVID-19 in the Omicron Era: Missed Opportunities in the Antiviral Treatment of SARS-CoV-2 InfectionsG Bartolucci, E Garro, M Mussa, et al.Journal of Neurovirology|August 7, 2015
Blood brain barrier impairment is associated with cerebrospinal fluid markers of neuronal damage in HIV-positive patientsA Calcagno, C Atzori, A Romito, et al.Journal of Neurovirology|June 29, 2014
Prevalence and predictors of blood-brain barrier damage in the HAART eraA Calcagno, M C Alberione, A Romito, et al.Pageof 19